Stock Analysis
Formoplast AD (BUL:FORM) Full Year 2023 Results
Key Financial Results
- Revenue: лв1.72m (up 22% from FY 2022).
- Net income: лв98.0k (up from лв85.0k loss in FY 2022).
- Profit margin: 5.7% (up from net loss in FY 2022). The move to profitability was driven by higher revenue.
- EPS: лв0.026 (up from лв0.022 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Formoplast AD's share price is broadly unchanged from a week ago.
Risk Analysis
You should learn about the 3 warning signs we've spotted with Formoplast AD (including 2 which shouldn't be ignored).
Valuation is complex, but we're helping make it simple.
Find out whether Formoplast AD is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Simply Wall St
About BUL:FORM
Formoplast AD
Formoplast AD manufactures and sells plastic injection molds in Europe, Asia, and Africa.
Flawless balance sheet with acceptable track record.
